vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $18.6M, roughly 1.0× ENANTA PHARMACEUTICALS INC). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -64.1%, a 63.3% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs -25.7%). ENANTA PHARMACEUTICALS INC produced more free cash flow last quarter ($-11.8M vs $-15.8M). Over the past eight quarters, ENANTA PHARMACEUTICALS INC's revenue compounded faster (4.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
CTMX vs ENTA — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.6M |
| Net Profit | $-154.0K | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -60.5% |
| Net Margin | -0.8% | -64.1% |
| Revenue YoY | -25.7% | 9.8% |
| Net Profit YoY | 97.6% | 46.4% |
| EPS (diluted) | — | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $15.1M | ||
| Q2 25 | $18.7M | $18.3M | ||
| Q1 25 | $50.9M | $14.9M | ||
| Q4 24 | $38.1M | $17.0M | ||
| Q3 24 | $33.4M | $14.6M | ||
| Q2 24 | $25.1M | $18.0M | ||
| Q1 24 | $41.5M | $17.1M |
| Q4 25 | — | $-11.9M | ||
| Q3 25 | — | $-18.7M | ||
| Q2 25 | $-154.0K | $-18.3M | ||
| Q1 25 | $23.5M | $-22.6M | ||
| Q4 24 | $18.9M | $-22.3M | ||
| Q3 24 | $5.7M | $-28.8M | ||
| Q2 24 | $-6.5M | $-22.7M | ||
| Q1 24 | $13.8M | $-31.2M |
| Q4 25 | — | -60.5% | ||
| Q3 25 | — | -121.6% | ||
| Q2 25 | -6.9% | -103.2% | ||
| Q1 25 | 44.4% | -164.3% | ||
| Q4 24 | 46.4% | -138.8% | ||
| Q3 24 | 12.3% | -204.4% | ||
| Q2 24 | -33.7% | -134.6% | ||
| Q1 24 | 28.1% | -192.1% |
| Q4 25 | — | -64.1% | ||
| Q3 25 | — | -123.6% | ||
| Q2 25 | -0.8% | -99.7% | ||
| Q1 25 | 46.2% | -151.7% | ||
| Q4 24 | 49.6% | -131.4% | ||
| Q3 24 | 17.2% | -197.3% | ||
| Q2 24 | -26.0% | -126.1% | ||
| Q1 24 | 33.3% | -182.7% |
| Q4 25 | — | $-0.42 | ||
| Q3 25 | — | $-0.88 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-1.06 | ||
| Q4 24 | — | $-1.05 | ||
| Q3 24 | — | $-1.36 | ||
| Q2 24 | — | $-1.07 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $37.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $126.6M |
| Total Assets | $175.1M | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.4M | ||
| Q3 25 | — | $32.3M | ||
| Q2 25 | $49.0M | $44.8M | ||
| Q1 25 | $47.6M | $60.2M | ||
| Q4 24 | $38.1M | $84.3M | ||
| Q3 24 | $40.6M | $37.2M | ||
| Q2 24 | $43.2M | $35.8M | ||
| Q1 24 | $36.2M | $63.5M |
| Q4 25 | — | $126.6M | ||
| Q3 25 | — | $64.7M | ||
| Q2 25 | $119.9M | $79.3M | ||
| Q1 25 | $25.0M | $93.5M | ||
| Q4 24 | $-456.0K | $111.8M | ||
| Q3 24 | $-23.5M | $128.8M | ||
| Q2 24 | $-31.2M | $148.9M | ||
| Q1 24 | $-31.7M | $166.1M |
| Q4 25 | — | $329.5M | ||
| Q3 25 | — | $280.7M | ||
| Q2 25 | $175.1M | $301.0M | ||
| Q1 25 | $98.5M | $323.0M | ||
| Q4 24 | $120.5M | $348.6M | ||
| Q3 24 | $139.0M | $376.7M | ||
| Q2 24 | $159.2M | $398.8M | ||
| Q1 24 | $184.7M | $413.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-11.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $-11.8M |
| FCF MarginFCF / Revenue | -84.6% | -63.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.7M | ||
| Q3 25 | — | $-6.5M | ||
| Q2 25 | $-15.8M | $17.5M | ||
| Q1 25 | $-21.0M | $-13.5M | ||
| Q4 24 | $-19.9M | $-16.8M | ||
| Q3 24 | $-20.7M | $-10.4M | ||
| Q2 24 | $-19.5M | $-14.8M | ||
| Q1 24 | $-26.0M | $-28.6M |
| Q4 25 | — | $-11.8M | ||
| Q3 25 | — | $-7.9M | ||
| Q2 25 | $-15.8M | $17.4M | ||
| Q1 25 | $-21.2M | $-16.0M | ||
| Q4 24 | $-20.0M | $-25.5M | ||
| Q3 24 | $-20.7M | $-19.4M | ||
| Q2 24 | $-19.6M | $-21.3M | ||
| Q1 24 | $-26.2M | $-30.3M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -52.5% | ||
| Q2 25 | -84.6% | 94.7% | ||
| Q1 25 | -41.6% | -107.4% | ||
| Q4 24 | -52.5% | -150.6% | ||
| Q3 24 | -62.1% | -132.5% | ||
| Q2 24 | -78.2% | -118.6% | ||
| Q1 24 | -63.1% | -177.5% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | 0.1% | 0.8% | ||
| Q1 25 | 0.2% | 17.0% | ||
| Q4 24 | 0.2% | 51.6% | ||
| Q3 24 | 0.1% | 61.3% | ||
| Q2 24 | 0.4% | 36.4% | ||
| Q1 24 | 0.3% | 9.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
ENTA
Segment breakdown not available.
